Outstanding 24-Month Clinical Results - A Breakthrough in Coronary Artery Disease Repair
While much of the world’s focus is on life-stealer coronavirus, cardiovascular disease is still the number one cause of death globally. According to WHO statistics, 17.9 million people die from cardiovascular disease or an estimated 31% of all deaths worldwide.
Cardiovascular disease accounted for 29.3% of all deaths in Singapore in 2019, according to the Singapore Heart Foundation. This means that almost 1 out of 3 deaths is due to heart diseases or stroke. In fact, every day, 17 people die from cardiovascular disease (heart diseases and stroke) in Singapore.
Dr Antonio Colombo from the Humanitas Research Hospital in Milan, Italy, recently revealed the 24-month clinical results of an innovative, new treatment for coronary artery disease from Elixir Medical Corporation. Findings show DynamX Bioadaptor - a drug eluting stent that structurally behaves the same as a traditional metal stent, may very well be the only coronary technology designed to accommodate disease progression and improve blood flow to the heart.
As our heart beats, our blood vessels expand and contract, known as pulsatile motion. Commonly used metal stents placed within vessels prevent those vessels from exhibiting pulsatile motion. This may be a cause of or a compounding factor for restenosis (restenosis occurs when a section of blocked artery that was opened up with angioplasty or a stent has narrowed again) that may even lead to a cardiovascular disease to develop faster.
Drug eluting stents or DES do an efficient job supporting the coronary artery in the short term. But they permanently “cage”, or constrain, the vessel and show an adverse event rate that continues to build at a rate of 2-3% year-over-year, without end. DynamX Bioadaptor structurally behaves the same as a traditional metal stent, but after a few months becomes more flexible, allowing pulsatile motion to take over the vessel. Its special flexible segments throughout its architecture are held rigid by the polymer that releases the Novolimus antiproliferative drug embedded in it. The polymer is slowly eaten away by the body, releasing the drug, while also eventually letting loose the flexible segments. Once these segments are freed, the dynamics of the stent change to make it significantly more pliable. Besides helping to liberate the vessel to move naturally, the new design may help avoid fractures to the stent itself, which is a common occurrence.
DynamX Bioadaptor is currently available at the National Heart Centre and Tan Tock Seng Hospital in Singapore. It is also available commercially in Hong Kong and the United Arab Emirates. It will be soon available in Japan, Germany, Belgium, Sweden and New Zealand through a clinical trial. Roll out of DynamX is planned in Malaysia, Vietnam, Taiwan, Thailand, Middle East and select countries in Europe this year (2021).
If you or someone you know have cardiovascular disease needing attention, talk to a trusted heart specialist about DynamX Bioadaptor.
